Blasi Francesco, Bruckmann Chiara
Foundation FIRC Institute of Molecular Oncology (IFOM), 20139 Milan, Italy.
J Dev Biol. 2021 Oct 13;9(4):44. doi: 10.3390/jdb9040044.
Recently MEIS1 emerged as a major determinant of the MLL-r leukemic phenotype. The latest and most efficient drugs effectively decrease the levels of MEIS1 in cancer cells. Together with an overview of the latest drugs developed to target MEIS1 in MLL-r leukemia, we review, in detail, the role of MEIS1 in embryonic and adult hematopoiesis and suggest how a more profound knowledge of MEIS1 biochemistry can be used to design potent and effective drugs against MLL-r leukemia. In addition, we present data showing that the interaction between MEIS1 and PBX1 can be blocked efficiently and might represent a new avenue in anti-MLL-r and anti-leukemic therapy.
最近，MEIS1成为MLL-r白血病表型的主要决定因素。最新且最有效的药物能有效降低癌细胞中MEIS1的水平。结合针对MLL-r白血病中MEIS1研发的最新药物概述，我们详细综述了MEIS1在胚胎和成人造血过程中的作用，并提出如何利用对MEIS1生物化学更深入的了解来设计针对MLL-r白血病的强效且有效的药物。此外，我们展示的数据表明，MEIS1与PBX1之间的相互作用可被有效阻断，这可能代表了抗MLL-r和抗白血病治疗的新途径。
